InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations
dc.contributor.author | Singh, Dave | |
dc.contributor.author | Criner, Gerard J. | |
dc.contributor.author | Dransfield, Mark T. | |
dc.contributor.author | Halpin, David M. G. | |
dc.contributor.author | Han, MeiLan K. | |
dc.contributor.author | Lange, Peter | |
dc.contributor.author | Lettis, Sally | |
dc.contributor.author | Lipson, David A. | |
dc.contributor.author | Mannino, David | |
dc.contributor.author | Martin, Neil | |
dc.contributor.author | Martinez, Fernando J. | |
dc.contributor.author | Miller, Bruce E. | |
dc.contributor.author | Wise, Robert | |
dc.contributor.author | Zhu, Chang-Qing | |
dc.contributor.author | Lomas, David | |
dc.date.accessioned | 2022-08-10T18:25:01Z | |
dc.date.available | 2022-08-10T18:25:01Z | |
dc.date.issued | 2021-04-28 | |
dc.identifier.citation | Respiratory Research. 2021 Apr 28;22(1):130 | |
dc.identifier.uri | https://doi.org/10.1186/s12931-021-01706-y | |
dc.identifier.uri | https://hdl.handle.net/2027.42/173725 | en |
dc.description.abstract | Abstract Background Fibrinogen is the first qualified prognostic/predictive biomarker for exacerbations in patients with chronic obstructive pulmonary disease (COPD). The IMPACT trial investigated fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI and UMEC/VI in patients with symptomatic COPD at risk of exacerbations. This analysis used IMPACT trial data to examine the relationship between fibrinogen levels and exacerbation outcomes in patients with COPD. Methods 8094 patients with a fibrinogen assessment at Week 16 were included, baseline fibrinogen data were not measured. Post hoc analyses were performed by fibrinogen quartiles and by 3.5 g/L threshold. Endpoints included on-treatment exacerbations and adverse events of special interest (AESIs). Results Rates of moderate, moderate/severe, and severe exacerbations were higher in the highest versus lowest fibrinogen quartile (0.75, 0.92 and 0.15 vs 0.67, 0.79 and 0.10, respectively). The rate ratios (95% confidence interval [CI]) for exacerbations in patients with fibrinogen levels ≥ 3.5 g/L versus those with fibrinogen levels < 3.5 g/L were 1.03 (0.95, 1.11) for moderate exacerbations, 1.08 (1.00, 1.15) for moderate/severe exacerbations, and 1.30 (1.10, 1.54) for severe exacerbations. There was an increased risk of moderate/severe exacerbation (hazard ratio [95% CI]: highest vs lowest quartile 1.16 [1.04, 1.228]; ≥ 3.5 g/L vs < 3.5 g/L: 1.09 [1.00, 1.16]) and severe exacerbation (1.35 [1.09, 1.69]; 1.27 [1.08, 1.47], respectively) with increasing fibrinogen level. Cardiovascular AESIs were highest in patients in the highest fibrinogen quartile. Conclusions Rate and risk of exacerbations was higher in patients with higher fibrinogen levels. This supports the validity of fibrinogen as a predictive biomarker for COPD exacerbations, and highlights the potential use of fibrinogen as an enrichment strategy in trials examining exacerbation outcomes. Trial registration: NCT02164513 | |
dc.title | InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations | |
dc.type | Journal Article | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/173725/1/12931_2021_Article_1706.pdf | |
dc.identifier.doi | https://dx.doi.org/10.7302/5456 | |
dc.language.rfc3066 | en | |
dc.rights.holder | The Author(s) | |
dc.date.updated | 2022-08-10T18:25:00Z | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.